A necrotic stimulus is required to maximize matrix-mediated myogenesis in mice

Autor: Maria Grazia Berardinelli, Antonio Musarò, Erik J. Suuronen, Drew Kuraitis

Publikováno v: Disease Models & Mechanisms
Disease Models & Mechanisms, Cambridge Company of Biologists, 2013, 6 (3), pp.793-801. ⟨10.1242/dmm.011072⟩
Disease Models & Mechanisms; Vol 6
Disease Models & Mechanisms, Vol 6, Iss 3, Pp 793-801 (2013)

Summary Biomaterials that are similar to skeletal muscle extracellular matrix have been shown to augment regeneration in ischemic muscle. In this study, treatment with a collagen-based matrix stimulated molecular myogenesis in an mdx murine model of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a188cae253c2d138dcac9a51c6d4c0
http://europepmc.org/articles/PMC3634661

Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle

Autor: Andrey A. Arzumanov, Michael J. Gait, Gabriela D. Ivanova, Matthew J.A. Wood, Bernard Lebleu, Rachida Abes, HaiFang Yin

Publikováno v: Nucleic Acids Research
Nucleic Acids Research, Oxford University Press, 2008, 36 (20), pp.6418-28. ⟨10.1093/nar/gkn671⟩

International audience; Steric blocking peptide nucleic acid (PNA) oligonucleotides have been used increasingly for redirecting RNA splicing particularly in therapeutic applications such as Duchenne muscular dystrophy (DMD). Covalent attachment of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff9bddf68630fe24f1c64525cd7b37e
https://doi.org/10.1093/nar/gkn671

P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy

Autor: Sinadinos, Anthony, Young, Christopher, Al-Khalidi, Rasha, Teti, Anna, Kalinski, Paweł, Mohamad, Shafini, Floriot, Léonore, Henry, Tiphaine, Tozzi, Gianluca, Jiang, Taiwen, Wurtz, Olivier, Lefebvre, Alexis, Shugay, Mikhail, Tong, Jie, Vaudry, David, Arkle, Stephen, doRego, Jean-Claude, Górecki, Dariusz, Peltz, Gary

Publikováno v: PLoS Medicine
PLoS Medicine, Public Library of Science, 2015, 12 (10), pp.e1001888. ⟨10.1371/journal.pmed.1001888⟩
Sinadinos, A, Young, C N J, Al-Khalidi, R, Teti, A, Kalinski, P, Mohamad, S, Floriot, L, Henry, T, Tozzi, G, Jiang, T, Wurtz, O, Lefebvre, A, Shugay, M, Tong, J, Vaudry, D, Arkle, S, doRego, J-C & Górecki, D C 2015, ' P2RX7 purinoceptor : a therapeutic target for ameliorating the symptoms of Duchenne muscular dystrophy ', PLoS Medicine, vol. 12, no. 10, e1001888 . https://doi.org/10.1371/journal.pmed.1001888
PLoS Medicine, Vol 12, Iss 10, p e1001888 (2015)

Background Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease, leading to severe disability and death in young men. Death is caused by the progressive degeneration of striated muscles aggravated by sterile inflammation. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c29e7193baff110df68550c5b59fb092
https://hal-normandie-univ.archives-ouvertes.fr/hal-02058099

Rescue of a dystrophin-like protein by exon skipping in vivo restores GABAA-receptor clustering in the hippocampus of the mdx mouse

Autor: Olivier Danos, Carole Gruszczynski, Luis Garcia, Cyrille Vaillend, Carine Ros, Caroline Perronnet, Elise Peltekian, Aurélie Goyenvalle, Serge Laroche

Publikováno v: Molecular Therapy
Molecular Therapy, Cell Press, 2010, 18 (9), pp.1683-8. ⟨10.1038/mt.2010.134⟩
Molecular Therapy, Nature Publishing Group, 2010, 18 (9), pp.1683-8. 〈10.1038/mt.2010.134〉
Molecular Therapy, 2010, 18 (9), pp.1683-8. ⟨10.1038/mt.2010.134⟩
Molecular Therapy, Nature Publishing Group, 2010, 18 (9), pp.1683-8. ⟨10.1038/mt.2010.134⟩

International audience; Dystrophin, the cytoskeletal protein whose defect is responsible for Duchenne muscular dystrophy (DMD), is normally expressed in both muscles and brain. Genetic loss of brain dystrophin in the mdx mouse model of DMD reduces th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f295ef525e906cdda3fc9bf68967a0
https://hal.archives-ouvertes.fr/hal-01183355

The Rag2–Il2rb–Dmd– Mouse: a Novel Dystrophic and Immunodeficient Model to Assess Innovating Therapeutic Strategies for Muscular Dystrophies

Autor: Christian A. J. Vosshenrich, Vincent Mouly, Libero Vitiello, Gillian Butler-Browne, James P. Di Santo, Ahmed Aamiri, Ernst-Martin Füchtbauer, Denis Vallese, Elisa Negroni, Capucine Trollet, Arnaud Ferry, Stephanie Duguez

Publikováno v: Molecular Therapy
Molecular Therapy, 2013, 21 (10), pp.1950-7. ⟨10.1038/mt.2013.186⟩
Molecular Therapy, Cell Press, 2013, 21 (10), pp.1950-7. ⟨10.1038/mt.2013.186⟩
Vallese, D, Negroni, E, Duguez, S, Ferry, A, Trollet, C, Aamiri, A, Vosshenrich, C A, Füchtbauer, E-M, Di Santo, J P, Vitiello, L, Butler-Browne, G & Mouly, V 2013, ' The Rag2-I/2rb-Dmd-Mouse : a Novel Dystrophic and Immunodeficient Model to Assess Innovating Therapeutic Strategies for Muscular Dystrophies ', Molecular Therapy, vol. 21, no. 10, pp. 1950-1957 . https://doi.org/10.1038/mt.2013.186

The development of innovative therapeutic strategies for muscular dystrophies, particularly cell-based approaches, is still a developing field. Although positive results have been obtained in animal models, they have rarely been confirmed in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb6073d71c46ad3754708ab78e33014a
https://europepmc.org/articles/PMC3808143/